Fujian Akeylink Biotechnology Co., Ltd.
Clinical trials sponsored by Fujian Akeylink Biotechnology Co., Ltd., explained in plain language.
-
New drug combo aims to silence hepatitis b virus
Disease control Recruiting nowThis phase II trial tests whether two experimental drugs, GST-HG131 and GST-HG141, can safely reduce hepatitis B surface antigen (HBsAg) levels in people with chronic hepatitis B. The study involves 80 adults aged 35-65. Participants receive either the drug combination or a place…
Phase: PHASE2 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could help hepatitis b patients who Don't respond to standard care
Disease control Recruiting nowThis Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…
Phase: PHASE3 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC